Paper37246765
Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
Larsson AT and 27 others. Neuro Oncol, 2023. Cited by 15 papers, by iCite.
Cite this record
ConductScience Library. Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. Papers, record 37246765. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37246765
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neurofibrosarcoma | Major topic |
| Neurofibromatosis 1 | Major topic |
| Nerve Sheath Neoplasms | Major topic |
| Humans | |
| Precision Medicine | |
| Mutation |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 NS115438 | NINDS NIH HHS | United States | R01NS115438 | PubMed | NIH RePORTER |
| UH3 CA244687 | NCI NIH HHS | United States | UH3CA244687 | PubMed and NIH | NIH RePORTER |
References47
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30389682 | PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia. | EMBO Mol Med | 2018 | https://conductscience.org/library/papers/30389682 | PubMed |
| 2 | 28483691 | 3D tumor microtissues as an in vitro testing platform for microenvironmentally-triggered drug delivery systems. | Acta Biomater | 2017 | https://conductscience.org/library/papers/28483691 | PubMed |
| 3 | 18242512 | Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. | Cancer Cell | 2008 | https://conductscience.org/library/papers/18242512 | PubMed |
| 4 | 30341162 | Maftools: efficient and comprehensive analysis of somatic variants in cancer. | Genome Res | 2018 | https://conductscience.org/library/papers/30341162 | PubMed |
| 5 | 9610699 | Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors. | Cancer | 1998 | https://conductscience.org/library/papers/9610699 | PubMed |
| 6 | 24055055 | Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. | Cell Rep | 2013 | https://conductscience.org/library/papers/24055055 | PubMed |
| 7 | 18984156 | Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow. | Cell | 2008 | https://conductscience.org/library/papers/18984156 | PubMed |
| 8 | 30722027 | Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas. | Neuro Oncol | 2019 | https://conductscience.org/library/papers/30722027 | PubMed |
| 9 | 32561749 | A clinically and genomically annotated nerve sheath tumor biospecimen repository. | Sci Data | 2020 | https://conductscience.org/library/papers/32561749 | PubMed |
| 10 | 34647023 | A genetic mouse model with postnatal Nf1 and p53 loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumor. | Neurooncol Adv | 2021 | https://conductscience.org/library/papers/34647023 | PubMed |
| 11 | 32353955 | New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. | Genes (Basel) | 2020 | https://conductscience.org/library/papers/32353955 | PubMed |
| 12 | 32352002 | Human Organ-Specific 3D Cancer Models Produced by the Stromal Self-Assembly Method of Tissue Engineering for the Study of Solid Tumors. | Biomed Res Int | 2020 | https://conductscience.org/library/papers/32352002 | PubMed |
| 13 | 29117388 | Neurofibromatosis Type 1-Associated MPNST State of the Science: Outlining a Research Agenda for the Future. | J Natl Cancer Inst | 2017 | https://conductscience.org/library/papers/29117388 | PubMed |
| 14 | 32647357 | Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma. | Commun Biol | 2020 | https://conductscience.org/library/papers/32647357 | PubMed |
| 15 | 24576830 | Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. | Cancer Res | 2014 | https://conductscience.org/library/papers/24576830 | PubMed |
| 16 | 32642731 | Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives. | Neurooncol Adv | 2020 | https://conductscience.org/library/papers/32642731 | PubMed |
| 17 | 27268795 | The Ensembl Variant Effect Predictor. | Genome Biol | 2016 | https://conductscience.org/library/papers/27268795 | PubMed |
| 18 | 24695404 | Trimmomatic: a flexible trimmer for Illumina sequence data. | Bioinformatics | 2014 | https://conductscience.org/library/papers/24695404 | PubMed |
| 19 | 25516281 | Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. | Genome Biol | 2014 | https://conductscience.org/library/papers/25516281 | PubMed |
| 20 | 19740389 | Trabectedin. | Br J Clin Pharmacol | 2009 | https://conductscience.org/library/papers/19740389 | PubMed |
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42973577 | Human leucocyte antigen class I and II alleles are associated with tumor susceptibility in neurofibromatosis type 1. | Front Immunol | 2026 | https://conductscience.org/library/papers/42973577 | PubMed |
| 42713391 | Combination of EZH2 and MEK inhibitors as an effective therapy for neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. | Neurooncol Adv | 2026 | https://conductscience.org/library/papers/42713391 | PubMed |
| 42579369 | Combined FAK and MEK inhibition suppresses chromosome 8 gain malignant peripheral nerve sheath tumors. | J Clin Invest | 2026 | https://conductscience.org/library/papers/42579369 | PubMed |
| 42310314 | Induced pluripotent stem cell-derived models of malignant nerve sheath tumor progression mimic glial to neuro-mesenchymal transition and uncover therapeutic opportunities. | Nat Commun | 2026 | https://conductscience.org/library/papers/42310314 | PubMed |
| 41973374 | Drug sensitivity testing of patient-derived bone sarcomas identifies selective kinase inhibitors for patients with refractory disease. | Clin Transl Oncol | 2026 | https://conductscience.org/library/papers/41973374 | PubMed |
| 41294711 | Neurofibromatosis Type 1 and the Search for Effective Tumor Therapies Using High-Throughput Drug Screening. | Curr Oncol | 2025 | https://conductscience.org/library/papers/41294711 | PubMed |
| 41007664 | Ex Vivo Traceability Platform for Phospholipoproteomic Formulations: Functional Evidence Without Clinical Exposure. | Biomedicines | 2025 | https://conductscience.org/library/papers/41007664 | PubMed |
| 40664660 | Integrated genomic analysis of NF1-associated peripheral nerve sheath tumors: an updated biorepository dataset. | Sci Data | 2025 | https://conductscience.org/library/papers/40664660 | PubMed |
| 40553452 | MTA-Cooperative PRMT5 Inhibitors Are Efficacious in MTAP-Deleted Malignant Peripheral Nerve Sheath Tumor Models. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40553452 | PubMed |
| 40063513 | DLK1 Distinguishes Subsets of NF1-Associated Malignant Peripheral Nerve Sheath Tumors with Divergent Molecular Signatures. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40063513 | PubMed |
| 39857962 | A Sequencing Overview of Malignant Peripheral Nerve Sheath Tumors: Findings and Implications for Treatment. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/39857962 | PubMed |
| 39857943 | UBR5 in Tumor Biology: Exploring Mechanisms of Immune Regulation and Possible Therapeutic Implications in MPNST. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/39857943 | PubMed |
| 39620202 | Multiomic analyses reveal new targets of polycomb repressor complex 2 in Schwann lineage cells and malignant peripheral nerve sheath tumors. | Neurooncol Adv | 2024 | https://conductscience.org/library/papers/39620202 | PubMed |
| 38710002 | Contemporary Approach to Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors. | Am Soc Clin Oncol Educ Book | 2024 | https://conductscience.org/library/papers/38710002 | PubMed |
| 38000020 | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Sci Adv | 2023 | https://conductscience.org/library/papers/38000020 | PubMed |
| 37798904 | Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities. | Mol Oncol | 2024 | https://conductscience.org/library/papers/37798904 | PubMed |
Genes17
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37246765
GET https://conductscience.org/api/papers/v1/37246765/authors?page=2